Clinical trial · Interventional
Effect of Casodex on Tumour Hypoxia - Prostate Cancer
A Study of the Effect of Neoadjuvant Bicalutamide (Casodex) on Tumour Hypoxia in Patients With Clinically Localized Prostate Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Prostate cancers, in common with many other tumours, are often hypoxic; that is, they have low levels of oxygen. It is thought that tumour hypoxia may hasten the progression of cancers and make them more resistant to treatment. One previous study has suggested that hormone therapy, such as Casodex, may improve the prostate oxygen level. This study is designed to test that finding.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Prostatic Neoplasms | Prostate Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| hypoxia measurement | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- hypoxia measurement
- description
- Patients undergoing or planning to receive combined anti-androgen (Casodex) and radiotherapy
- interventionNames
- Procedure: hypoxia measurement
Primary outcomes (4)
- measure
- To determine the effect of neoadjuvant anti-androgen therapy on oxygenation of prostatic tumours
- timeFrame
- 8 weeks
- description
- Trans-rectal ultrasound and measurement of tumor oxygenation
- measure
- Correlate level of tumor oxygenation with PSA level
- timeFrame
- 8 weeks
- description
- PSA test (ug/L)
Eligibility
Eligibility (as posted)
- Sex
- Male
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Men with histologically proven prostatic carcinoma, stage cT2, N0, M0, receiving neoadjuvant bicalutamide plus conformal radiotherapy in study 9907, who have previously participated in the prostate cancer hypoxia project * informed consent Exclusion Criteria: * Coagulopathy
References
Publications (0)
Data not yet available